Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

9.620 +0.030 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 928,722
Open 9.530
Bid (Size) 9.630 (1)
Ask (Size) 9.840 (25)
Prev. Close 9.590
Today's Range 9.380 - 9.840
52wk Range 7.720 - 31.55
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
7 Small-Cap Stocks to Buy BEFORE the Year-End Rally
explore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy 
Via InvestorPlace

Performance

YTD
-61.40%
-61.40%
1 Month
+18.18%
+18.18%
3 Month
-10.34%
-10.34%
6 Month
-64.26%
-64.26%
1 Year
-62.16%
-62.16%

More News

Read More
From laggards to leaders: Small caps on the rise
Via MarketBeat
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
What 8 Analyst Ratings Have To Say About Vir Biotechnology
Via Benzinga
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For November 2, 2023
Via Benzinga
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
From Vir Biotechnology, Inc.
Via Business Wire
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
Via InvestorPlace
7 Biotech Stocks to Get In Now Before Investors Catch On
Via InvestorPlace
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
From Vir Biotechnology, Inc.
Via GlobeNewswire
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Planet Labs PBC, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.